170291-52-8

Basic information

• Product Name: 1-Piperidinecarboxylic acid, 4-(4-fluorophenyl)-4-(hydroxymethyl)-, 1,1-dimethylethyl ester
• CAS NO: 170291-52-8
• Molecular Formula: C17H24FNO3
• Molecular Weight: 309.381
• Mol File: 170291-52-8.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: 1-Piperidinecarboxylic acid, 4-(4-fluorophenyl)-4-(hydroxymethyl)-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Piperidinecarboxylic acid, 4-(4-fluorophenyl)-4-(hydroxymethyl)-, 1,1-dimethylethyl ester(170291-52-8)
• EPA Substance Registry System: 1-Piperidinecarboxylic acid, 4-(4-fluorophenyl)-4-(hydroxymethyl)-, 1,1-dimethylethyl ester(170291-52-8)

Safety Data

• Hazardous Substances Data: 170291-52-8(Hazardous Substances Data)

Usage

| Molecular weight

| 389.47 g/mol |

| Chemical structure

| 1-Piperidinecarboxylic acid, 4-(4-fluorophenyl)-4-(hydroxymethyl)-, 1,1-dimethylethyl ester |

| Synonyms

| Tadalafil |

| Medicinal use

| Treatment of erectile dysfunction and benign prostatic hyperplasia |

| Mechanism of action

| Phosphodiesterase 5 (PDE5) inhibitor, relaxes muscles, and increases blood flow to certain areas of the body |

| Administration

| Taken as needed, about 30 minutes before sexual activity |

| Duration

| Can last in the system for up to 36 hours |

| Side effects

| May include headache, stomach upset, muscle pain, and back pain |

| Precautions

| Consult with a healthcare professional before use to ensure it is safe and appropriate |

Upstream product

• 644981-89-5 1-(tert-butoxycarbonyl)-4-(4-fluorophenyl)piperidine-4-carboxylic acid 
• 1368648-25-2 C₁₂H₁₆FNO 
• 24424-99-5 di-tert-butyl dicarbonate 
• 643756-79-0 C₁₇H₂₂FNO₃ 
• 1429661-32-4 C₁₉H₂₆FNO₄ 
• 627-11-2 2-Chloroethyl chloroformate 

Downstream Products

• 954124-01-7 tert-butyl 4-((3-bromo-5-(trifluoromethyl)benzyloxy)methyl)-4-(4-fluorophenyl)piperidine-1-carboxylate 
• 1100207-73-5 tert-butyl 4-(4-fluorophenyl)-4-((1-(5-(trifluoromethyl)quinolin-8-yl)ethoxy)methyl)piperidine-1-carboxylate 
• 672926-84-0 1-N-t-BOC-4-(4-fluorophenyl)-4-[(3-cyano-2,4-dimethoxynaphth-1-yl)methoxymethyl]piperidine 
• 1100212-79-0 tert-butyl 4-(4-fluorophenyl)-4-(((5-(trifluoromethyl)-((2-(trimethylsilyl)methoxy)methyl)-1H-indazol-7-yl)methoxy)methyl)piperidine-1-carboxylate 
• 1100212-95-0 (+/-)-tert-butyl 4-(4-fluorophenyl)-4-((1-(5-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-7-yl)ethoxy)methyl)piperidine-1-carboxylate 
• 1100215-16-4 (+/-)-tert-butyl 4-((1-(5-chloro-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-7-yl)ethoxy)methyl)-4-(4-fluorophenyl)piperidine-1-carboxylate 
• 1100213-72-6 (+/-)-tert-butyl 4-((1-(5-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-7-yl)ethoxy)methyl)-4-(4-fluorophenyl)piperidine-1-carboxylate 
• 1100214-23-0 (+/-)-tert-butyl 4-(4-fluorophenyl)-4-((1-(5-methoxy-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-7-yl)ethoxy)methyl)piperidine-1-carboxylate 
• 1100214-52-5 (+/-)-tert-butyl 4-((1-(5-fluoro-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-7-yl)ethoxy)methyl)-4-(4-fluorophenyl)piperidine-1-carboxylate 
• 1100214-91-2 (+/-)-tert-butyl 4-((1-(3-bromo-5-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-7-yl)ethoxy)methyl)-4-(4-fluorophenyl)piperidine-1-carboxylate 
• 1100215-14-2 (+/-)-tert-Butyl 4-((1-(5-chloro-2-cyclopropyl-2H-indazol-7-yl)ethoxy)methyl)-4-(4-fluorophenyl)piperidine-1-carboxylate 
• 1100215-45-9 tert-butyl 4-(4-fluorophenyl)-4-((((5-(trifluoromethyl)-1-((2-trimethylsilyl)ethoxy)methyl)-1H-indol-7-yl)methoxy)methyl)piperidine-1-carboxylate 
• 1100215-74-4 tert-butyl 4-(4-fluorophenyl)-4-(((6-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d][1,2,3]triazol-4-yl)methoxy)methyl)piperidine-1-carboxylate 
• 1100216-08-7 tert-butyl 4-((1-(5-chloro-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-7-yl)-2-methoxy-2-oxoethoxy)methyl)-4-(4-fluorophenyl)piperidine-1-carboxylate 

Relevant articles and documents

Development of a scalable route to a dual NK-1/serotonin receptor antagonist

The evolution of a process for the preparation of a new heterocyclic dual NK1/serotonin receptor antagonist is described. The final synthesis features a telescoped sequence in which an iron(III)-catalyzed Grignard coupling is followed by a benzylic chlori

SUBSTITUTED HETEROCYCLIC ETHERS AND THEIR USE IN CNS DISORDERS

The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating CNS disorders.

NK-1 AND SEROTONIN TRANSPORTER INHIBITORS

The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating disorders associated with an excess or imbalance of tachykinins or serotonin or both.